The FDA has missed the deadline for making a key decision regarding a Novavax (NVAX.US) Covid-19 vaccine, days after the Food and Drug Administration’s vaccine chief was pushed out. Novavax’s application needed more data and was unlikely to be approved soon - was said by people familiar with a matter, citted by WSJ.
This information is seriously damaging the sentiment around the company and is undermining its current ability to maintain its business system. The shares are losing over 1.5%, although at one point the declines were as high as 4%.

Source: xStation
UBS raises Micron’s price target. Shares are rising!
US OPEN: Wall Street not afraid of Shutdown 📈💲
DE40: Europan market still under pressure of weak industry and political turmoil
Daily summary: US100 surges almost 1% 📈Crypto and precious metals on the rise